Data from the OrigAMI-4 trial support the accelerated approval of amivantamab and hyaluronidase-lpuj for this HNSCC population.
|Articles|July 14, 2009
- ONCOLOGY Vol 23 No 8
- Volume 23
- Issue 8
US Oncology Launches Oncology-Specific EHR
US Oncology, Inc, announced the launch of iKnowMed-an oncology-specific electronic health record (EHR) system designed by oncologists for oncologists-to the open market.
Advertisement
US Oncology, Inc, announced the launch of iKnowMed-an oncology-specific electronic health record (EHR) system designed by oncologists for oncologists-to the open market. Features of iKnowMed include oncology-specific terminology, decision support, outcomes reporting, and imaging reports.
Articles in this issue
over 17 years ago
Resolving Confusion: The New Realities of Mantle Cell Lymphomaover 17 years ago
Reishi Mushroomover 17 years ago
Unraveling the Mystery of a Supraclavicular Massover 17 years ago
Effective Local Therapy and Long-Term Survival in Breast Cancerover 17 years ago
Local Therapy MattersAdvertisement
Related to this article
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.
Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
The FDA assigned an April 9, 2027, target action date to resubmitted applications for rivoceranib plus camrelizumab in unresectable or metastatic hepatocellular carcinoma.
Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence, and the data that shaped his approach.
Data from the phase 3 MANGROVE study support the application for zanubrutinib/rituximab in this mantle cell lymphoma population.
Sunnie Kim, MD, discussed perioperative durvalumab plus FLOT, ctDNA-guided de-escalation, irAE monitoring, and biomarkers in gastroesophageal cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
Setting Up an HDR Brachytherapy Program Amid a National Decline
3
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
4
16-Fraction PMRT With IMN Irradiation Noninferior in High-Risk Breast Cancer
5